Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rocket Pharmaceuticals, Inc.

6.33
+0.18002.93%
Post-market: 6.400.0689+1.09%19:58 EDT
Volume:2.20M
Turnover:13.86M
Market Cap:674.97M
PE:-2.32
High:6.39
Open:6.13
Low:6.09
Close:6.15
Loading ...

Rocket Pharmaceuticals Inc - Prices Upsized Public Offering of 13.2 Mln Shares at $12.50/Share

THOMSON REUTERS
·
11 Dec 2024

Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

THOMSON REUTERS
·
11 Dec 2024

Rocket Pharmaceuticals Plans $150 Million Public Offering of Common Shares

MT Newswires Live
·
11 Dec 2024

Rocket Pharmaceuticals announces $150M common stock offering

TIPRANKS
·
11 Dec 2024

BRIEF-Rocket Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Reuters
·
11 Dec 2024

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
11 Dec 2024

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire
·
11 Dec 2024

Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference

Business Wire
·
26 Nov 2024

Rocket Pharmaceuticals on Track for Lowest Close Since September 2022 -- Data Talk

Dow Jones
·
21 Nov 2024

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Benzinga
·
20 Nov 2024

Rocket Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald

Dow Jones
·
19 Nov 2024

Sector Update: Health Care Stocks Lean Lower Premarket Tuesday

MT Newswires Live
·
19 Nov 2024

TD Cowen Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
19 Nov 2024

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
19 Nov 2024

Rocket Pharmaceuticals to Resume Patient Enrollment in RP-L301 Gene Therapy Phase 2 Trial in 2025

MT Newswires Live
·
19 Nov 2024

Rocket Pharmaceuticals has not initiated enrollment in Phase 2 RP-L301 study

TIPRANKS
·
19 Nov 2024

Rocket Pharmaceuticals announces publication of Phase 1 RP-A501 long-term data

TIPRANKS
·
19 Nov 2024

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

Business Wire
·
19 Nov 2024

Scotiabank Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
15 Nov 2024

Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions

Business Wire
·
13 Nov 2024